Wall Street brokerages predict that Oncomed Pharmaceuticals Inc (NASDAQ:OMED) will post ($0.19) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Oncomed Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.37) and the highest estimate coming in at ($0.07). Oncomed Pharmaceuticals posted earnings of $0.25 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 176%. The business is scheduled to issue its next earnings report on Thursday, March 14th.
According to Zacks, analysts expect that Oncomed Pharmaceuticals will report full-year earnings of ($0.37) per share for the current financial year, with EPS estimates ranging from ($0.50) to ($0.16). For the next year, analysts forecast that the firm will post earnings of ($0.88) per share, with EPS estimates ranging from ($1.55) to ($0.41). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Oncomed Pharmaceuticals.
Oncomed Pharmaceuticals (NASDAQ:OMED) last posted its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.16 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.36. Oncomed Pharmaceuticals had a return on equity of 25.81% and a net margin of 10.98%. The firm had revenue of $19.52 million during the quarter, compared to analysts’ expectations of $7.97 million.
Several research analysts have recently weighed in on OMED shares. HC Wainwright decreased their price target on Oncomed Pharmaceuticals from $3.00 to $2.00 and set a “neutral” rating for the company in a research note on Friday, September 21st. Zacks Investment Research cut Oncomed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 11th. Finally, ValuEngine cut Oncomed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 2nd.
OMED stock opened at $1.69 on Friday. Oncomed Pharmaceuticals has a 1-year low of $1.52 and a 1-year high of $5.56. The firm has a market capitalization of $71.23 million, a PE ratio of -1.63 and a beta of 1.99.
Institutional investors have recently bought and sold shares of the stock. Macquarie Group Ltd. purchased a new stake in Oncomed Pharmaceuticals during the second quarter valued at $186,000. Essex Investment Management Co. LLC purchased a new stake in Oncomed Pharmaceuticals during the third quarter valued at $205,000. Connor Clark & Lunn Investment Management Ltd. increased its position in Oncomed Pharmaceuticals by 60.8% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 100,691 shares of the biopharmaceutical company’s stock valued at $233,000 after acquiring an additional 38,091 shares during the last quarter. Alambic Investment Management L.P. purchased a new stake in Oncomed Pharmaceuticals during the second quarter valued at $254,000. Finally, Acadian Asset Management LLC purchased a new stake in Oncomed Pharmaceuticals during the second quarter valued at $320,000. Institutional investors own 48.75% of the company’s stock.
Oncomed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway.
See Also: Risk Tolerance
Get a free copy of the Zacks research report on Oncomed Pharmaceuticals (OMED)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.